[Federal Register Volume 72, Number 141 (Tuesday, July 24, 2007)]
[Notices]
[Pages 40331-40332]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-14266]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 24, 2007, Applied 
Science Labs, Division of Alltech Associates Inc., 2701 Carolean 
Industrial Drive, State College, Pennsylvania 16801, made application 
by renewal to the Drug Enforcement Administration (DEA) to be 
registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
4-Methylaminorex (cis isomer) (1590).......  I
Alpha-ethyltryptamine (7249)...............  I

[[Page 40332]]

 
Lysergic acid diethylamide (7315)..........  I
2, 5-Dimethoxy-4-n-propylthiophenethylamine  I
 (2C-T-7) (7348).
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2-5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
Alpha-methyltryptamine (AMT) (7432)........  I
Bufotenine (7433)..........................  I
Diethyltryptamine (7434)...................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
5-methoxy-N-,N-diisopropyltryptamine(5-MeO-  I
 DIPT) (7439).
N-Ethyl-1-phenylcyclohexylamine (7455).....  I
1-(1-Phenylcyclohexyl)pyrrolidine (PCPy)     I
 (7458).
1[1-(2 Thienyl)cyclohexyl]piperidine (7470)  I
Dihydromorphine (9145).....................  I
Normorphine (9313).........................  I
Methamphetamine (1105).....................  II
1-Phenylcylohexylamine (7460)..............  II
Phencyclidine (7471).......................  II
Phenylacetone (8501).......................  II
1-Piperidinocyclohexanecarbonitrile (8603).  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Benzoylecgonine (9180).....................  II
Meperidine intermediate-B (9233)...........  II
Noroxymorphone (9668)......................  II
------------------------------------------------------------------------

    The company plans to manufacture high purity drug standards used 
for analytical application only in clinical, toxicological, and 
forensic laboratories.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 2401 
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than September 24, 2007.

    Dated: July 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-14266 Filed 7-23-07; 8:45 am]
BILLING CODE 4410-09-P